Front Oncol: Anlotinib combined with PD-1 inhibitors are effective and controllable in the treatment of advanced solid tumors

The combination of immune checkpoint inhibitors (ICIs) and anti- vascular therapy is the current direction of cancer treatment
.

Anlotinib (AL3818) is a new type of multi-target tyrosine kinase inhibitor (TKI) that targets the vascular endothelial growth factor receptor (VEGFR) to inhibit tumor growth

The combination of immune checkpoint inhibitors (ICIs) and anti- vascular therapy is the current direction of cancer treatment

Since January 2019, 26 patients with advanced cancer have received treatment, including lung cancer, gallbladder cancer, endometrial cancer,Gastric cancer , pancreatic cancer , penile cancer and melanoma
.

The patients received combined Anlotinib (12mg) once a day, from day 1 to day 14 (21 days as a course of treatment), and anti-PD-1 antibody was added every 3 weeks until progressed or intolerable toxicity

Since January 2019, 26 patients with advanced cancer have received treatment, including lung cancer, gallbladder cancer, endometrial cancer,Gastric cancer , pancreatic cancer , penile cancer and melanoma

Among the 26 patients included, 13 males (50.

The primary endpoint of the study is ORR and DCR
.

The ORR of 26 patients was 23.

The primary endpoint of the study is ORR and DCR

The median follow-up time was 9.
0 months (range 4.
97-20.
43 months), and 8 patients died
.

The median progression-free survival (PFS) of all patients was 4.

The median follow-up time was 9.

Overall, 46.
15% of patients experienced treatment-related AEs
.

There were 9 cases of grade 1-2 adverse events (34.

Overall, 46.

Compared with the non-responding group, Anlotinib combined with anti-PD-1 antibody significantly decreased CD4+ T cells in the blood (p<0.
05), and both groups of CD8+ T cells decreased
.
The ratio of CD4+/CD8+ T cells in the response group decreased, while the ratio of CD4+/CD8+ T cells in the non-response group was the opposite
.
However, there was no significant difference in the amount of CD8+ T cell changes and the ratio of CD4/8 between the two groups
.

In summary, the study shows that Anlotinib combined with PD-1 inhibitors has a certain curative effect and controllable toxicity in the treatment of advanced solid tumors
.

In summary, the study shows that Anlotinib combined with PD-1 inhibitors has a certain curative effect and controllable toxicity in the treatment of advanced solid tumors
.
The study shows that anlotinib combined with PD-1 inhibitors has a certain curative effect and controllable toxicity in the treatment of advanced solid tumors
.
The study shows that anlotinib combined with PD-1 inhibitors has a certain curative effect and controllable toxicity in the treatment of advanced solid tumors
.

Original source:

Original source:

Yuan M, Zhu Z, Mao W, Wang H, Qian H, Wu J, Guo X and Xu Q (2021) Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced RefractorySolid Tumors: A Single-Center, Observational, Prospective Study.
Front.
Oncol.
11:683502.
doi: 10.
3389/fonc.
2021.
683502

Yuan M, Zhu Z, Mao W, Wang H, Qian H, Wu J, Guo X and Xu Q (2021) Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced RefractorySolid Tumors: A Single-Center, Observational, Prospective Study.
Front.
Oncol.
11:683502.
doi: 10.
3389/fonc.
2021.
683502 Leave a message here